^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Drug:datopotamab deruxtecan (DS-1062a) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO Asia 2023
    Title:

    509MO - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

    Published date:
    11/27/2023
    Excerpt:
    Confirmed ORRs were 26.4% (Dato-DXd) and 12.8% (DTX), with median DORs of 7.1 and 5.6 mo….PFS was significantly improved with Dato-DXd over DTX in pts with pretreated adv/met NSCLC.
    Trial ID:
    TROPION-LUNG01
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Daiichi Sankyo Press Release
    Title:

    Datopotamab Deruxtecan Met Dual Primary Endpoint of ProgressionFree Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

    Published date:
    07/03/2023
    Excerpt:
    Topline results from the TROPION-Lung01 phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.
    Trial ID:
    TROPION-LUNG01